Announcements Trials
Browse Landscape

Status

Available 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 93Observational 4Expanded_access 3

Sponsor

Cancer Type

Myeloid 3Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

venetoclax 1selinexor 1ruxolitinib 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Primary Myelofibrosis × Clear all
NCT07215832 2026-03-02

KEAP

Karyopharm Therapeutics Inc

Available
GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Novartis

Available
Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT03592576 2024-05-06

Expanded Access to Navitoclax

AbbVie

No longer available
LymphoidMyeloidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡